Ottobock stock holds outlook as reimbursement pressure rises

Ottobock delivered stronger third-quarter revenue and profitability on Thursday, November 12, but warned that reimbursement conditions are becoming more demanding in several key markets. The company kept its 2026 outlook unchanged while preparing investors for a more moderate seasonal uplift in the fourth quarter.

The figures were reported in the company's EQS announcement and covered by AD HOC NEWS.

Growth Remains Broadly Intact

Core revenue rose 9.0 percent year over year to 433.4 million euros in the third quarter. Organic core revenue growth reached 6.4 percent. Products and Components led the expansion with organic growth of 9.9 percent, while Patient Care grew 1.7 percent as longer reimbursement approvals weighed on business-to-consumer momentum.

Regional performance was uneven. Organic core revenue increased 8.0 percent in EMEA and 17.9 percent in APAC, while the Americas declined 1.8 percent. For the first nine months, core revenue rose 8.1 percent to 1,251.8 million euros, with organic growth of 6.6 percent.

Margins Cushion Market Pressure

Underlying core EBITDA rose 13.5 percent to 120.1 million euros, lifting the margin by 110 basis points to 27.7 percent. Ottobock attributed the improvement to product mix, scale effects and cost management. Underlying net income increased 5.8 percent to 52.9 million euros in the quarter.

Ottobock stock traded at 39.68 euros on Lang & Schwarz at 17:48 CET on Thursday, November 12, 2026. The quote was 8.74 percent below the 43.48-euro Lang & Schwarz quote at 11:44 CET in the previous report published on the same day; this is a separate comparison from the Xetra daily close.

Guidance Holds Into Fourth Quarter

Management continues to target organic core revenue growth of 6.0 to 8.0 percent in 2026 and an underlying core EBITDA margin above 27.0 percent. Chief Executive Oliver Jakobi said the group continued to outperform the market, while reimbursement frameworks were evolving in several markets. Guidance for 2027 is scheduled with the full-year 2026 results in March 2027.

Germany's DAX market provides the broader setting for investor sentiment around German equities. Current DAX market reports.

More news and analyses on Ottobock stock.